Caris Downgrades Endo Pharmaceuticals (ENDP) to Average, Raises Price Target

Article Stock Quotes (1) Comments (0)

Caris & Co. downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) to an Average rating from its previous rating of Above Average. They are also raising their price target to $38 from from $28.

For more ratings news on Endo Pharmaceuticals Holdings Inc click here and for the rating history of Endo Pharmaceuticals Holdings Inc click here.

Shares of Endo Pharmaceuticals Holdings Inc closed at $36.46 yesterday, with a 52 week range of $19.11-$38.20.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Jefferies Downgrades First Republic Bank (FRC) to Hold
• Buckingham Research Upgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Buy

Create E-mail Alert Related Categories

Downgrades

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?